#Argentina #Buenos Aires #biotechnology #Biosidus #Agalsidase Beta

Expanding Capabilities in Biopharmaceutical Manufacturing

Biosidus, a leading biotechnology company based in Argentina, has recently announced the operational status of its new bioreactor plant. This significant development enhances the firm’s production capacity for biopharmaceuticals, enabling them to respond more effectively to the burgeoning international demand for complex biological treatments. With over 40 years of experience in the development and manufacture of biosimilar medicines, Biosidus is now positioning itself to meet urgent needs in the healthcare sector.

The establishment of this new facility represents a vital segment of Biosidus's industrial platform, particularly as healthcare systems worldwide emphasize the importance of dependable manufacturing processes, treatment continuity, and diversified sources for complex biopharmaceuticals. Notably, the company’s flagship product, agalsidase beta, has emerged as a crucial element of this strategy. It serves as a biosimilar used in enzyme replacement therapy for treating Fabry disease, and reflects the growing focus within the company on addressing rare diseases.

Mario Koch, the director of the Rare Diseases Division at Biosidus, commented on the importance of treatment continuity, especially for patients coping with rare and chronic ailments. He emphasized, "The expansion of our manufacturing capacity strengthens our commitment to making Biosidus’s biotechnological capabilities accessible to healthcare systems in need of a stable and reliable supply of high-quality biological products." This endeavor not only enhances supply chains but also supports the accessibility of vital treatments across different populations in various regions.

Since the launch of agalsidase beta in Argentina in 2025, Biosidus has embarked on an international expansion plan, geared to address pressing supply demands in markets where regulatory frameworks allow for the distribution of such therapies. The new bioreactor is part of a larger strategy that merges scientific capabilities, local production, industrial investments, and global outreach aimed at improving access to comprehensive biotherapeutic options.

About Biosidus

Biosidus is an Argentine biotechnology firm specializing in the development, manufacturing, and commercialization of biosimilar medicinal products. With vast global experience and expertise in biotechnologies, the company focuses on developing and producing complex biological drugs that span several therapeutic areas. Its unwavering dedication to innovation and quality continues to foster growth in the biopharmaceutical sector, allowing it to meet both national and international health demands effectively.

With these advancements, Biosidus is putting itself in an advantageous position to not only cater to existing market needs but also to establish itself as a key player in the global biopharmaceutical industry.